With tax loss selling drying up and volatility gone, I have started a position again in RMED. Pending FDA approval. Could see a huge gap up on any good news as liquidity has dried up in this ticker. $12 price target put on by analyst a few months ago.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
